"Oral Drug Stalls Clinically Definite MS"
Among 618 patients with clinically isolated syndrome, some 24 percent of those assigned to 14 mg/day of teriflunomide subsequently were diagnosed with full-blown MS after a second attack during two years of treatment, compared with 36 percent in those assigned to placebo (P=0.009), according to Aaron Miller, MD, Professor of Neurology, and Director of Clinical Affairs at the Corinne Goldsmith Dickinson Center for Multiple Sclerosis of the Icahn School of Medicine at Mount Sinai. Dr. Miller said that the study, called TOPIC, was the first to show that an oral agent can reduce the risk of progression in patients with clinically isolated syndrome. Similar results had been reported earlier for interferon-beta drugs and glatiramer acetate (Copaxone). Learn more
Scientists Develop Novel Approach to Enhance Drug Delivery for Brain Tumors in Children
Mar 02, 2023 View All Press Releases
Researchers Identify the Role of an Alzheimer’s Disease Risk Gene in the Brain
Nov 30, 2022 View All Press Releases
